Hangzhou-based gene therapy company Exegenesis Bio Inc said on Tuesday that it has closed a Series B+ round funding raising “tens of millions of US dollars” led by LYFE Capital, a Chinese healthcare fund with $1.27 billion in assets under management.
Continue reading with Data Vantage
Venture-backed company data in SE Asia, India, Pakistan, Bangladesh.
Instant investment updates and valuations.
Tailored search, 3 monthly reports.
Industry-trusted platform.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
